569results about "Macromolecular non-active ingredients" patented technology

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

The present invention discloses compositions and methods comprising enriched bisdemethoxycurcumin (BDMC) present at 20% by weight or greater for use in inhibiting receptor for advanced glycation end products (RAGE) expression in a subject with a chronic inflammatory condition. The composition further comprises beta-amyrin palmitate (BAP). The present invention also discloses the use of the composition in managing a chronic inflammatory condition in a subject.

This invention relates to soba tertide (N succinyl-[Glu 9 ,Ala 11,15 This invention relates to a composition for promoting the proliferation and protection of existing neuroepithelium of cochlear and vestibular cells located within the otolaryngeal vesicle using endothelin B receptor agonists such as endothelin 1 (IRL-1620). The composition is administered systemically via transtympanic membrane, cochlear fenestration, or intravenously or intramuscularly. This invention also relates to a method for treating sensorineural hearing loss and vestibular symptoms caused by inner ear cell degeneration by using compounds containing endothelin analogs, through mechanisms of neuroprotection and neurogenesis of cochlear vestibular hair cells and synapses.

The present application relates to a kind of high elasticity double-network hydrogel and its preparation method and application, belong to new material preparation field.A kind of high elasticity double-network hydrogel, the double-network hydrogel is formed by the crosslinking of first network and second network, wherein the first network is the gel network that gelatin-TG enzyme is crosslinked, the second network is the gel network that sodium alginate-calcium ion is crosslinked.The stability of gelatin-TG enzyme and the elasticity of sodium alginate-Ca 2+ The present application combines the stability of gelatin-TG enzyme and the elasticity of sodium alginate-Ca 2+ , significantly improves the elasticity and form stability of the non-backing fever patch;Through active ingredient pretreatment process, the problem of menthol and camphor being difficult to dissolve in water is solved, ensuring uniform dispersion;The preparation process is controllable, the product performance is stable, meets the dynamic fitting demand under human activity scene, effectively solves the technical pain points of traditional fever patch, has significant practical value and market prospect.

A composition contains a BCS Class II or IV drug that is acid-base solubilized with a pharmaceutically acceptable acid, and which is complexed with β-cyclodextrin. The β-cyclodextrin complexed drug exhibits enhanced bioavailability. The drug may be formulated for oral administration and / or to exhibit rapid release when administered. Preferable compositions may contain no crosslinked or polymerized non-active components.

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluorophenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

The present invention is directed to the use of ASC (Apoptosis Associated Speck-Like Protein Containing CARD) specks in the cancer immunotherapy. The present invention also relates to the compositions containing an ASC speck carrier formed by ASC proteins, and a tumor antigen for the treatment of cancer cells and tumors.

The application provides a polymerizable human serum albumin bio-ink material and a preparation method and application thereof. The polymerizable human serum albumin is human serum albumin modified by a group containing an unsaturated bond structure. According to the technical scheme of the application, human serum albumin and a compound containing an acrylate structure are used as reaction monomers to perform a reaction, wherein the human serum albumin has good biocompatibility; and the reaction product, the polymerizable human serum albumin, can be used for culturing cells after solidification, and has application prospects of replacing Matrigel used for culturing organoids; in particular, the application can also change the mechanical properties and flexibility of a printed sample by adjusting the concentration of the bio-ink, so as to realize the possibility of oral administration and in-vivo implantation, and expand the application range of the bio-3D printing technology in the biomedical field.

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (Dol) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

The application discloses an active oxygen response type bacteriostatic and repair promoting hydrogel and a preparation method and application thereof, the hydrogel is formed by disulfide bond cross-linked hydrogel in response to active oxygen free radicals in the vagina of vaginitis patients through thiol modified hyaluronic acid (HASH), and can enhance in-vivo retention by thiol and vaginal tissue interaction. Cationic surfactant such as didecyldimethylammonium chloride (DDAC) as the bacteriostatic component of the hydrogel, efficiently killing pathogenic bacteria while having good biocompatibility, and is not prone to cause bacterial drug resistance. As a natural immune regulator, beta-glucan regulates the vaginal microenvironment, promotes the polarization of macrophages into anti-inflammatory M2 type and promotes cell migration, etc., to promote the repair of the vaginal immune barrier, regulate the vaginal flora, and reduce the probability of vaginitis recurrence. The HASH hydrogel provides an efficient, convenient and highly transformative potential strategy to provide more choices for the treatment of vaginitis.

The application relates to the technical field of biomedical materials, in particular to a self-lubricating anti-degradation hydrogel core-shell microsphere, a preparation method and application. The microsphere comprises a core and a shell layer; the core is a gel micro-core formed by photo-crosslinking of a photo-cured monomer; the gel micro-core is loaded with a drug; the shell layer is a lubricating anti-degradation layer formed by photo-crosslinking polymerization of a hydrophilic zwitterionic polymer and polyethylene glycol diacrylate after blending; the particle size of the core is 45-280 mu m, and the thickness of the shell layer is 0.1-20 mu m. The scheme provided in the application can load the drug in the core and provide the lubricating anti-degradation function, solves the problems of insufficient lubrication persistence, high enzymatic degradation sensitivity and uncontrollable drug release in the joint cavity, and has the advantages of long-acting lubrication, anti-degradation and controllable drug slow release.

This invention proposes a Gynostemma pentaphyllum tea bag and its processing technology, belonging to the field of tea bag technology. The tea bag comprises the following raw materials in parts by weight: 60-80 parts Gynostemma pentaphyllum, 6-12 parts wild chrysanthemum, 5-10 parts Acer truncatum tea, 3-6 parts nervonic acid microcapsules, and 4-8 parts licorice. The processing technology includes: raw material pretreatment, chopping, segmented roasting, pulverizing, mixing, sterilization, and packaging. This invention, through a unique formula design, effectively improves the bitter taste of Gynostemma pentaphyllum using licorice and wild chrysanthemum; it increases the water solubility of nervonic acid by utilizing the wall structure of the microcapsules, solving the problem of its insolubility in water, allowing nervonic acid to be effectively dissolved in the tea infusion, achieving the effects of brain nerve protection and repair. Simultaneously, the microcapsule protection system ensures its dispersibility and stability in the processing system; through the combination of segmented roasting and ultra-fine pulverization, it not only alleviates the cold nature of Gynostemma pentaphyllum but also significantly improves the extraction rate of effective components.

The present invention belongs to the field of ophthalmology, specifically the development of advanced ophthalmic collyria. This domain covers pharmaceutical formulations for treating chronic eye diseases. The developed technology combines innovative approaches in ocular tribology and tear film bioengineering, focusing on the restoration of the rheological properties of the tear film to improve the lubrication, stability and health of the eye surface. In addition, the invention falls within the sphere of controlled-release ophthalmic formulations, with technologies that optimise surface tension, osmolarity and viscosity, providing a more effective and longer lasting therapeutic solution.

The application discloses application of mesenchymal stem cell spheroids in preparation of a preparation for treating osteoarthritis, and relates to the technical field of cell therapy and osteoarthritis treatment, and specifically comprises mesenchymal stem cell spheroids with an average diameter of 120-180 mu m and a solution containing 0.5%-10% human serum albumin. The cells are prepared into 120-180 mu m cell spheroids, and the solution containing specific concentration human serum albumin is used as a carrier, so that the cell survival rate is stabilized at more than 90%, and high-activity delivery is realized; the optimized size ensures smooth injection and long-term retention in the joint cavity, and overcomes the shortcoming that single cells are easily removed; after joint cavity injection, the preparation can synergistically promote bone reconstruction and cartilage repair, and produces clear curative effects such as bone mass increase of more than 30%, cartilage degeneration score reduction of more than 50%, and the like, which are quantifiable and verifiable, so that a stable, long-acting and curative drug preparation and application scheme are provided for osteoarthritis treatment.

This invention relates to the field of health food and pharmaceutical preparation technology, specifically to a method for preparing ginsenoside freeze-dried flash-release tablets. These ginsenoside freeze-dried flash-release tablets are made from the following raw materials in the indicated weight ratios: 3-5 parts ginseng extract, 8-12 parts matrix support agent, 1.5-2.5 parts binder, and 0.3-0.5 parts prebiotics. The method includes the following steps: S1, ingredient dissolution; S2, high-speed emulsification; S3, vacuum degassing; S4, quantitative filling; S5, ultra-low temperature quick-freezing; S6, programmed freeze-drying; and S7, aluminum-aluminum sealed packaging. This invention has the advantages of convenient administration, rapid absorption, pure formulation, good stability, and excellent taste.

The application belongs to the technical field of biological medicine, and particularly relates to a composite material containing a local anesthetic and a preparation method thereof. The composite material containing the local anesthetic comprises the following raw materials in parts by weight: bupivacaine hydrochloride 10-15 parts, a light-heat conversion agent 4-8 parts, delta-cadinene 0.5-1 part, a penetration enhancer 1-3 parts, and glycerol 2-5 parts. The light-heat conversion agent and the bupivacaine hydrochloride are added in combination, so that the discomfort caused by photothermal therapy is relieved. The delta-cadinene and the bupivacaine hydrochloride are combined, so that the analgesic effect is improved, the analgesic time is prolonged, the pain caused by frequent dressing change is avoided, and the toxic side effects caused by the accumulation of blood drug concentration are avoided. In addition, the penetration enhancer composed of egg membrane protein peptide and polylysine is introduced, so that the absorption of the effective components by the skin is further promoted, and the analgesic effect is quickly exerted.

This specification describes a formulation comprising a homogeneous suspension of a biopolymer(s) for drug delivery of an active molecule. In an embodiment, the biopolymer is selected from chitin, chitosan, cellulose, hemicellulose, lignin, amylose, actin, fibrin, collagen, silk, fibroin, keratin, wool, alginic acid, and mixtures thereof. In an embodiment, the biopolymer is mechanically treated with an API under high shear conditions and / or high mechanical energy. The formulation can find particular use in drug delivery systems that involve the transport and release of compounds or molecules for purposes such as pharmaceuticals, drug substances, cosmetics, and the like.

A composition for treating cancer is provided, comprising a DDB2 inhibitor and a chemotherapeutic agent, wherein the DDB2 inhibitor comprises three RNA fragments derived from lincRNA-p21. Furthermore, the DDB2 inhibitor enhances the chemosensitivity of cancer to chemotherapeutic agents for the treatment of cancers that are unresponsive to chemotherapy.

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.

The application discloses a vitamin D-ovalbumin peptide composition, which comprises vitamin D3, ovalbumin peptide, a water-soluble auxiliary solubilizing stabilizer, an isotonic buffer regulator, an anti-oxidation bacteriostatic agent and a solvent in a residual amount, wherein the solvent is water. Compared with the prior art, the application has the advantages that a vitamin D-ovalbumin peptide composition with high stability and synergistic effect can be widely used in food, health products and medicines, and a preparation method and application thereof are provided.

This invention relates to a polypeptide for gene delivery, a polypeptide / nucleic acid molecular complex prepared therefrom, and its applications. The polypeptide of this application has the structure shown in Formula I, wherein Formula I contains an immune cell targeting group represented by Y. The polypeptide developed in this application, as a gene delivery carrier, has a highly efficient nucleic acid loading capacity. Furthermore, it exhibits high delivery efficiency to immune cells both in vitro and in vivo, thus showing broad application prospects in the immune cell-targeted delivery of genes.

The present invention relates to a crosslinkable liquid composition for use in a method of treating an eye disease of a subject eye, comprising (i) polyethylene glycol diacrylate (PEGDA), (ii) gelatin or a gelatin-based crosslinkable biomaterial, and (iii) a photoinitiator and optionally a coinitiator, the method comprising applying the crosslinkable liquid composition to the anterior corneal surface of the eye having the eye disease using a mold, crosslinking the crosslinkable liquid composition on the anterior corneal surface of the eye, thereby obtaining a composition crosslinked on the anterior corneal surface of the eye, and correcting the curvature of the crosslinked composition.

This invention obtains a stable ezetimibesimvastatin pharmaceutical composition by combining β-cyclodextrin and sulfite antioxidants. This pharmaceutical composition has better stability and satisfactory dissolution effect than the reference formulation. Furthermore, the preparation method of the ezetimibesimvastatin pharmaceutical composition of this invention is simple, the process does not require the use of organic solvents, and no special treatment is required, making it very suitable for industrial production.

The application discloses a lyophilized powder of Evf and a preparation method thereof. The lyophilized powder comprises recombinant human acidic fibroblast growth factor, excipient, protein protective agent, pH buffer and lyophilized preparation maintenance agent. The lyophilized powder prepared by the method has high stability and is not easy to be broken into powder in the shaking process, so that electrostatic is avoided due to the friction between the broken powder and the bottle wall in the storage and transportation process, and the product quality is improved.

This invention belongs to the field of biomedical aesthetics and skin repair, and provides an adipose stem cell exosome collagen microneedle patch for facial photoaging repair and its preparation method. This invention co-prepares adipose stem cell exosomes with collagen, trehalose, and a divalent metal ion source to form a lyophilized powder intermediate A. Sodium hyaluronate and collagen are used as the soluble matrix for the needle tip, and polyvinylpyrrolidone is used as the base and backing material. A soluble microneedle array is formed by centrifugal gradient assembly, overcoming the triple contradiction of needle strength and rapid dissolution, high solids content molding and exosome temperature loading, and lyophilization stability and immediate dissolution upon application. The product completely dissolves in 30 to 60 minutes after being applied to the skin. Exosomes synergistically release collagen transdermally, achieving targeted repair of photoaging. This solves the problems of poor needle consistency, insufficient stability of active ingredients, and low reliability in existing microneedle systems, and has broad application value in the field of facial photoaging aesthetics and functional skincare.

To provide therapies for subjects suffering from NAFLD.SOLUTION: A double stranded ribonucleic acid (RNAi) agent for inhibiting expression of Patatin-Like Phospholipase Domain Containing 3 is used which comprises a sense strand and an antisense strand. The sense strand comprises at least 15 contiguous nucleotides differing by 3 or less nucleotides from a specific nucleotide sequence. The antisense strand comprises at least 15 contiguous nucleotides differing by 3 or less nucleotides from another specific nucleotide sequence.SELECTED DRAWING: Figure 1

The application provides an AAV9 capsid protein variant and use thereof. Research finds that the AAV9 capsid protein is modified, and the modified amino acid sequence is shown in SEQ ID NO: 1, which can significantly escape neutralizing antibodies, and has significant positive significance for gene therapy.

The application belongs to the field of food functional factor processing, and particularly relates to a water-in-oil-in-water composite emulsion embedding lactoferrin, a preparation method and application. The W1 / O / W2 double emulsion system is constructed by a two-step method, and the leakage and inactivation risks of lactoferrin and VD3 in the preparation, storage and processing processes are effectively reduced through the double barrier effect of the oil phase film and the outer water phase film. Under the optimized sodium caseinate and gellan gum compounding conditions, the encapsulation rate of lactoferrin can be up to 82.52%, which proves that the structure has obvious advantages in improving the loading efficiency of active substances, and can significantly improve the encapsulation rate and structural stability of lactoferrin. The water-in-oil-in-water composite emulsion system prepared by the application can significantly improve the retention rate of lactoferrin in the digestion process, enhance the tolerance of lactoferrin to the gastrointestinal environment, and then enhance the arrival rate of lactoferrin in the intestinal tract, thereby improving the overall bioavailability.